File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/00000658-199508000-00007
- Scopus: eid_2-s2.0-0029133133
- PMID: 7543740
- WOS: WOS:A1995RM73400007
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor
Title | Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor |
---|---|
Authors | |
Issue Date | 1995 |
Citation | Annals of Surgery, 1995, v. 222, n. 2, p. 155-162 How to Cite? |
Abstract | Objective: The authors determined whether untreated breast cancer patients have elevated plasma levels of transforming growth factor-β1 (TGF-β1). Summary Background Data: Increased plasma TGF-β1 levels recently were found after chemotherapy in patients with advanced breast cancer. However, it currently is unknown whether this elevation in plasma TGF-β1 is caused by chemotherapy-induced normal tissue damage or whether it results from the presence of the tumor. Methods: An enzyme-linked immunosorbent assay was used to measure plasma TGF-β1 levels in 26 newly diagnosed breast cancer patients before and after definitive surgery. Patients were grouped by postoperative tumor status: 1) negative lymph nodes (group 1); 2) positive lymph nodes (group 2); and 3) overt residual disease (group 3). The site of TGF-β1 production in the tumors was localized by immunohistochemistry and in situ hybridization. Results: Plasma TGF-β1 levels were elevated preoperatively in 81% of the patients; TGF-β2 and TGF-β3 were undetectable. The preoperative TGF-β1 levels in the three patient groups were similar; however, the postoperative plasma TGF-β1 levels differed by disease status. The mean plasma TGF-β1 level in group 1 (n = 12) normalized after surgery (19.3 ± 3.2 vs. 5.5 ± 1.0 ng/mL, p < 0.081). In contrast, the mean plasma TGF-β1 levels remained above normal in both group 2 (n = 9) and group 3 (n = 5) after surgery. Transforming growth factor-β1 expression was found to be preferentially increased in the tumor stroma. Conclusions: Breast tumors result in increased plasma TGF-β1 levels in 81% of patients. After surgical removal of the primary tumor, the plasma TGF-β1 level normalizes in the majority of patients; persistently elevated levels correlate with the presence of lymph node metastases or overt residual tumor. These findings suggest that the usefulness of TGF-β1 as a potential plasma marker for breast tumors deserves further study. |
Persistent Identifier | http://hdl.handle.net/10722/266757 |
ISSN | 2023 Impact Factor: 7.5 2023 SCImago Journal Rankings: 2.729 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kong, F. M. | - |
dc.contributor.author | Anscher, M. S. | - |
dc.contributor.author | Murase, T. | - |
dc.contributor.author | Abbott, B. D. | - |
dc.contributor.author | Iglehart, J. D. | - |
dc.contributor.author | Jirtle, R. L. | - |
dc.date.accessioned | 2019-01-31T07:19:30Z | - |
dc.date.available | 2019-01-31T07:19:30Z | - |
dc.date.issued | 1995 | - |
dc.identifier.citation | Annals of Surgery, 1995, v. 222, n. 2, p. 155-162 | - |
dc.identifier.issn | 0003-4932 | - |
dc.identifier.uri | http://hdl.handle.net/10722/266757 | - |
dc.description.abstract | Objective: The authors determined whether untreated breast cancer patients have elevated plasma levels of transforming growth factor-β1 (TGF-β1). Summary Background Data: Increased plasma TGF-β1 levels recently were found after chemotherapy in patients with advanced breast cancer. However, it currently is unknown whether this elevation in plasma TGF-β1 is caused by chemotherapy-induced normal tissue damage or whether it results from the presence of the tumor. Methods: An enzyme-linked immunosorbent assay was used to measure plasma TGF-β1 levels in 26 newly diagnosed breast cancer patients before and after definitive surgery. Patients were grouped by postoperative tumor status: 1) negative lymph nodes (group 1); 2) positive lymph nodes (group 2); and 3) overt residual disease (group 3). The site of TGF-β1 production in the tumors was localized by immunohistochemistry and in situ hybridization. Results: Plasma TGF-β1 levels were elevated preoperatively in 81% of the patients; TGF-β2 and TGF-β3 were undetectable. The preoperative TGF-β1 levels in the three patient groups were similar; however, the postoperative plasma TGF-β1 levels differed by disease status. The mean plasma TGF-β1 level in group 1 (n = 12) normalized after surgery (19.3 ± 3.2 vs. 5.5 ± 1.0 ng/mL, p < 0.081). In contrast, the mean plasma TGF-β1 levels remained above normal in both group 2 (n = 9) and group 3 (n = 5) after surgery. Transforming growth factor-β1 expression was found to be preferentially increased in the tumor stroma. Conclusions: Breast tumors result in increased plasma TGF-β1 levels in 81% of patients. After surgical removal of the primary tumor, the plasma TGF-β1 level normalizes in the majority of patients; persistently elevated levels correlate with the presence of lymph node metastases or overt residual tumor. These findings suggest that the usefulness of TGF-β1 as a potential plasma marker for breast tumors deserves further study. | - |
dc.language | eng | - |
dc.relation.ispartof | Annals of Surgery | - |
dc.title | Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/00000658-199508000-00007 | - |
dc.identifier.pmid | 7543740 | - |
dc.identifier.scopus | eid_2-s2.0-0029133133 | - |
dc.identifier.volume | 222 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 155 | - |
dc.identifier.epage | 162 | - |
dc.identifier.isi | WOS:A1995RM73400007 | - |
dc.identifier.issnl | 0003-4932 | - |